Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Gliomas are one of the most lethal types of cancers accounting for ∼80% of all central nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 15 months. Recent molecular characterization studies...
Main Authors: | Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar A. Mujeeb, Michael R. Olin, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.680021/full |
Similar Items
-
Murine brain tumor microenvironment immunophenotyping using mass cytometry
by: Brandon L. McClellan, et al.
Published: (2022-06-01) -
Impact of epigenetic reprogramming on antitumor immune responses in glioma
by: Brandon L. McClellan, et al.
Published: (2023-01-01) -
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
by: Maria B. Garcia-Fabiani, et al.
Published: (2021-06-01) -
Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
by: Andrea Franson, et al.
Published: (2022-09-01) -
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models
by: Santiago Haase, et al.
Published: (2022-11-01)